title: Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity.
abstract: OBJECTIVE
  To explore the effect of resveratrol on B-cell leukemia/lymphoma-2 (Bcl-2) and vascular endothelial growth factor (VEGF) expression in rats with oxygen-induced retinopathy of prematurity (ROP).
  
  
  METHODS
  Seven-day-old Sprague-Dawley rats (N = 60) were randomly assigned to five groups. Group A received normal partial oxygen pressure and groups B, C, D, and E received 75% ± 2% oxygen for 5 days to induce ROP. The rats in groups C, D, and E were intragastrically treated with resveratrol (10, 30, and 60 mg/kg/d, respectively) once daily for 5 days. Rats were killed at 17 days of age and the retina was collected.
  
  
  RESULTS
  Western blot analysis revealed increased Bcl-2 protein expression in group B versus group A. Levels of Bcl-2 decreased with the increase of resveratrol concentration in groups C, D, and E. The optical density of Bcl-2 protein expression in group B was four times higher than that in group A (P < .01). When compared with group B, expression of Bcl-2 and VEGF in groups C, D, and E decreased in a dose-dependent manner. Significant differences in expression of Bcl-2 and VEGF were also noted among the three treatment groups with resveratrol (P < .01). After treatment with resveratrol at 10, 30, and 60 mg/kg/d, the inhibition rate of Bcl-2 expression was 11.1%, 38.1%, and 69.8% and that of VEGF expression was 3.4%, 23.0%, and 43.7%, respectively.
  
  
  CONCLUSIONS
  Resveratrol can significantly inhibit expression of Bcl-2 and VEGF in the retina of neonatal rats with oxygen-induced ROP. It may provide a protective effect on retinal neovascular diseases, including ROP.
authors.affiliation: Department of Ophthalmology, Shenzhen Children’s Hospital, 7019# Yitian Road, Futian District, Shenzhen, China. wenlinli6688@hotmail.com
authors.forename: Wenlin
authors.initials: W
authors.lastname: Li
authors.forename: Deyong
authors.initials: D
authors.lastname: Jiang
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D015153:Blotting, Western; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007231:Infant, Newborn; D010100:Oxygen / Q000633:toxicity; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D012178:Retinopathy of Prematurity / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D000975:Antioxidants; D010975:Platelet Aggregation Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D013267:Stilbenes; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000077185:Resveratrol; D010100:Oxygen